Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
Date:4/23/2009

n the recently completed Phase Ib clinical trial of ANA598 in HCV patients in a late-breaker poster entitled, "Antiviral Activity of ANA598, a Potent Non-Nucleoside Polymerase Inhibitor, In Chronic Hepatitis C Patients," at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL). In the Phase Ib study, ANA598 treatment resulted in rapid and sustained reductions in HCV RNA with median reductions at end of treatment (Day 4) exceeding 2 log10 (>99%) at all dose levels. At 200 mg bid, the median viral load reduction was 2.4 log10 (range of 0.4 to 3.4); at 400 mg bid, 2.3 log10 (range of 1.6 to 3.5); and at 800 mg bid, 2.9 log10 (range of 2.2 to 3.4). Genotype 1a patients demonstrated median reductions of 1.4 log10, 1.8 log10, and 2.5 log10 at 200, 400 and 800 mg bid, respectively. In 10 of the 12 genotype 1a patients who received ANA598, viral load was still declining at the end of the three days of treatment. Genotype 1b patients demonstrated median reductions of 2.6 log10, 2.5 log10 and 3.2 log10, at 200, 400 and 800 mg bid, respectively. No patient showed evidence of viral rebound while on ANA598. ANA598 was well-tolerated in this short term study and there were no serious adverse events.

  • 14-day Healthy Volunteer Study. Anadys recently completed dosing healthy volunteers in a 14-day study conducted to extend the safety and pharmacokinetic profile of ANA598. Thirty subjects participated in the study, with eight subjects receiving ANA598 and two subjects receiving placebo at each dose level (400 mg once-daily, 800 mg once-daily and 600 mg bid). Subjects received a single dose on day one followed by pharmacokinetic assessment over days two and three and received subsequent doses consecutively on days four through fourteen. Preliminary results from the study indicate that ANA598 was generally well-tolerated in all cohorts with no serious adverse events, al
    '/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of ... the three months and full year ended December ... Results:Revenue for the quarter ended December 31, 2014 ... fourth quarter of 2013 and $1.5 million for ...
(Date:3/26/2015)... The Market Element LLC, a leading inbound marketing ... Gig LLC to provide website design, development, and creative ... alliance with Designing Gig represents a pivotal moment for ... end-to-end, digital solution for our clients, which now includes ... president of The Market Element. “For small and mid-sized ...
(Date:3/26/2015)... 26, 2015 Neogen Corporation (NASDAQ: NEOG ... third quarter of fiscal 2015, which ended Feb. 28, ... year,s $6,575,000. Earnings per share in the current quarter ... year-to-date net income increased 17% over prior year to ... $0.56 per share, for the same period a year ...
(Date:3/26/2015)... March 26, 2015 "In America," the popular ... United States that is hosted by legendary film actor James ... of botany in an upcoming segment. , Botany is ... reality it is actually quite a bit more complicated than ... different types of living organisms, from the smallest bacteria known ...
Breaking Biology Technology:Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8
... Drives Physician Prescribing of Copaxone over an Interferon-Beta Therapy, According ... ... Resources, WALTHAM, Mass., March 11 Decision ... pharmaceutical and,healthcare issues, finds that Teva Pharmaceutical,s Copaxone has the,greatest patient ...
... Biosystems,( http://www.altogen.com ) announced launch of new ... Altogen Custom Services focus on,providing specialized biotechnology ... generation of stably-expressing cell,lines, assay development, screening ... draw upon their unique experience with over,hundred ...
... -Advances Reported in All Three Clinical Programs, Including Launch of ... Bavituximab Phase ... Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company developing ... (HCV) infection, today announced financial results for,the third quarter of ...
Cached Biology Technology:Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 2Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 3Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services 2Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 2Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 3Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 4Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 5Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 6Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 7Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 8Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 9Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008 10
(Date:3/5/2015)... , March 5, 2015 In Brazil ... of companies already using these solutions and 42 percent planning ... the latter, approximately 25 percent of the companies will be ... While the majority of companies in the region are currently ... the hybrid model will command significant attention in the coming ...
(Date:3/3/2015)... , March 3, 2015 ... provider of advanced cryogenic logistics solutions for ... immunotherapies, stem cells, cell lines, clinical research ... medicine, today announced the expansion of its ... Centers, ("Fred Hutch") Clinical Research Division ...
(Date:3/2/2015)... March 2, 2015  Businesses have a new ... company Tharon Rankins Enterprises has announced the launch ... ultra-safe way for businesses to protect their customers, ... Beconux is a biometric transaction ... Functioning similarly to an ATM machine, the new ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Personal Data Protection Company Launches New Product 2
... GAINESVILLE, Fla. The wild pea pod is big and ... its parent plant. And yet, like a grounded teenager ... if it has a reasonable chance of escape. ... landscape devoted to wildlife corridors greenways that link woods ...
... Scientists from Scripps Institution of Oceanography at UC ... have captured unprecedented details of vibrant sea life ... documentations of new species and marine animals previously ... surveys at unexplored depths, have revealed disturbing declines ...
... the United States continues to develop alternative energy methods ... as one of the most commercially viable technologies. Corn ... loss of soil organic carbon (SOC) associated with the ... is of agricultural and environmental concern. ...
Cached Biology News:Rooted plants move mysteriously down greenways, scientists say 2Rooted plants move mysteriously down greenways, scientists say 3Expeditions reveal gulf of California's deep sea secrets, as well as human imprints 2Expeditions reveal gulf of California's deep sea secrets, as well as human imprints 3Expeditions reveal gulf of California's deep sea secrets, as well as human imprints 4Managing carbon loss 2
... Peptide microarrays containing peptidomimetics built on ... on-chip synthesis platform. These microarrays are ... Custom Peptide Microarray Service. ... is completely customer specified. Thousands of ...
... custom designed to meet your needs. Two ... features per array (2 arrays/1" x 3" ... (1 array/slide). Features ... This extended length delivers higher sensitivity compared ...
... Select Tissue Arrays are intended for laboratory ... were fixed in neutral buffered formalin and ... diagnosis was performed by certified pathologists. ... blocks and relocated into a new recipient ...
... Chemicon Select Tissue Arrays are intended for ... tissues were fixed in neutral buffered formalin ... and diagnosis was performed by certified pathologists. ... paraffin blocks and relocated into a new ...
Biology Products: